Sanofi (SNY) provided notice to Lexicon (LXRX) that it is terminating collaboration to develop, manufacture, and commercialize Zynquista
Tweet Send to a Friend
(Updated - July 26, 2019 4:16 PM EDT)Sanofi today announced topline results from three Phase 3 trials of ZynquistaTM (sotagliflozin) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
